Handel nachbörslich: 53.62

Arcellx Inc (ACLX)

Arcellx Inc Aktie (ACLX) Neueste Nachrichten

Arcellx Inc (ACLX)

Arcellx Inc Aktie (ACLX) Neueste Nachrichten

Private Equity Prowl: 3 Overlooked Stocks Primed for Buyout Bids - InvestorPlace

Stifel Nicolaus Boosts Arcellx (NASDAQ:ACLX) Price Target to $83.00 - Defense World

Evercore ISI Upgrades Arcellx (NASDAQ:ACLX) to "Strong-Buy" - MarketBeat

Arcellx (NASDAQ:ACLX) Upgraded at Evercore ISI - MarketBeat

Arcellx (NASDAQ:ACLX) Upgraded to “Strong-Buy” at Evercore ISI - Defense World

Arcellx shares target raised by Stifel on study design - Investing.com India

Arcellx shares target raised by Stifel on study design - Investing.com Canada

Arcellx (NASDAQ:ACLX) Shares Up 6.6% After Analyst Upgrade - MarketBeat

Arcellx (NASDAQ:ACLX) Price Target Increased to $83.00 by Analysts at Stifel Nicolaus - MarketBeat

Arcellx (NASDAQ:ACLX) PT Raised to $83.00 - MarketBeat

Arcellx shares target raised by Stifel on study design - Investing.com

Arcellx (NASDAQ:ACLX) Receives New Coverage from Analysts at Evercore ISI - Defense World

HC Wainwright Lowers Arcellx (NASDAQ:ACLX) Price Target to $80.00 - Defense World

Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo New Zealand News

Evercore ISI Group Initiates Coverage of Arcellx (ACLX) with Outperform Recommendation - MSN

Victory Capital Management Inc. Raises Position in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Evercore ISI Begins Coverage on Arcellx (NASDAQ:ACLX) - MarketBeat

Analyst Expectations For Arcellx's Future - Arcellx (NASDAQ:ACLX) - Benzinga

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic - Simply Wall St

Arcellx shares receive Outperform rating on strategic partnership - Investing.com Australia

Victory Capital Management Inc. Boosts Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Arcellx shares receive Outperform rating on strategic partnership By Investing.com - Investing.com Canada

Arcellx shares receive Outperform rating on strategic partnership - Investing.com

Arcellx shares receive Outperform rating on strategic partnership - Investing.com India

HC Wainwright Cuts Arcellx (NASDAQ:ACLX) Price Target to $80.00 - MarketBeat

Arcellx shares receive Outperform rating on strategic partnership By Investing.com - Investing.com UK

Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? - Yahoo Singapore News

Is Arcellx (NASDAQ:ACLX) A Risky Investment? - Simply Wall St

Arcellx First Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Arcellx (NASDAQ:ACLX) Trading Down 6.1% - Defense World

Kite, Arcellx announce advances in Anito-Cel Multiple Myeloma Program - Medical Dialogues

Arcellx (ACLX) Stock Forecast and Price Target 2024 - MarketBeat

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - Marketscreener.com

Arcellx (NASDAQ:ACLX) Stock Price Down 6.1% - MarketBeat

Arcellx (NASDAQ:ACLX) Announces Earnings Results, Beats Expectations By $0.37 EPS - MarketBeat

Notable Two Hundred Day Moving Average Cross - ACLX - Nasdaq

Arcellx Becomes Oversold (ACLX) - Nasdaq

Kite and Arcellx prepare to launch Phase III multiple myeloma trial - Clinical Trials Arena

Arcellx (NASDAQ:ACLX) Stock Price Down 6.1% - MarketBeat

Arcellx : IMMagine-3 Multi-center, Global, Phase 3 Randomized Control Clinical Trial Design - Marketscreener.com

Kite and Arcellx to start Phase 3 trial for myeloma therapy - Investing.com

Kite and Arcellx to start Phase 3 trial for myeloma therapy - Investing.com India

Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com - Investing.com UK

Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset - Seeking Alpha

Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Kite (GILD) and Arcellx (ACLX) Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program - StreetInsider.com

Arcellx Provides First Quarter 2024 Financial Results - Business Wire

Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset - Seeking Alpha

(ACLX) Trading Signals - Stock Traders Daily

Arcellx (NASDAQ:ACLX) Receives “Buy” Rating from Needham & Company LLC - Defense World

Ähnlich wie ACLX